• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过荧光共振能量转移成像评估含前列腺特异性膜抗原(PSMA)的内体的还原电位。

Evaluation of the reducing potential of PSMA-containing endosomes by FRET imaging.

作者信息

Venkatesh Chelvam, Shen Jiayin, Putt Karson S, Low Philip S

机构信息

Discipline of Chemistry, Indian Institute of Technology, Madhya Pradesh, Indore 453552, India.

Discipline of Bioscience and Biomedical Engineering, Indian Institute of Technology, Madhya Pradesh, Indore 453552, India.

出版信息

Cancer Drug Resist. 2021 Mar 19;4(1):223-232. doi: 10.20517/cdr.2020.84. eCollection 2021.

DOI:10.20517/cdr.2020.84
PMID:35582012
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9019189/
Abstract

: Ligand-targeted therapeutics are experiencing increasing use for treatment of human diseases due to their ability to concentrate a desired drug at a pathologic site while reducing accumulation in healthy tissues. For many ligand-targeted drug conjugates, a critical aspect of conjugate design lies in engineering release of the therapeutic payload to occur only after its internalization by targeted cells. Because disulfide bond reduction is frequently exploited to ensure intracellular drug release, an understanding of the redox properties of endocytic compartments can be critical to ligand-targeted drug design. While the redox properties of folate receptor trafficking endosomes have been previously reported, little is known about the trafficking of prostate-specific membrane antigen (PSMA), a receptor that is experiencing increasing use for drug targeting in humans. : To obtain this information, we have constructed a PSMA-targeted fluorescence resonance energy transfer pair that reports on disulfide bond reduction by changing fluorescence from red to green. : We show here that this reporter exhibits rapid and selective uptake by PSMA-positive cells, and that reduction of its disulfide bond proceeds steadily but incompletely following internalization. The fact that maximal disulfide reduction reaches only ~50%, even after 24 h incubation, suggests that roughly half of the conjugates must traffic through endosomes that display no reducing capacity. : As the level of disulfide reduction differs between PSMA trafficked and previously published folate trafficked conjugates, it also follows that not all internalizing receptors are translocated through similar intracellular compartments. Taken together, these data suggest that the efficiency of disulfide bond reduction must be independently analyzed for each receptor trafficking pathway when disulfide bond reduction is exploited for intracellular drug release.

摘要

由于能够将所需药物集中在病理部位,同时减少在健康组织中的积累,配体靶向疗法在人类疾病治疗中的应用越来越广泛。对于许多配体靶向药物偶联物而言,偶联物设计的一个关键方面在于设计治疗性有效载荷的释放,使其仅在被靶向细胞内化后才发生。由于二硫键还原常被用于确保细胞内药物释放,因此了解内吞小室的氧化还原特性对于配体靶向药物设计至关重要。虽然先前已报道了叶酸受体转运内体的氧化还原特性,但对于前列腺特异性膜抗原(PSMA)的转运了解甚少,PSMA是一种在人类药物靶向中应用越来越广泛的受体。

为了获得这些信息,我们构建了一个PSMA靶向的荧光共振能量转移对,通过将荧光从红色变为绿色来报告二硫键的还原情况。

我们在此表明,该报告分子在PSMA阳性细胞中表现出快速且选择性的摄取,并且其二硫键在内化后稳定但不完全地进行还原。即使在孵育24小时后,最大二硫键还原仅达到约50%,这一事实表明大约一半的偶联物必须通过没有还原能力的内体进行转运。

由于PSMA转运的偶联物与先前发表的叶酸转运的偶联物之间二硫键还原水平不同,因此也可以得出结论,并非所有内化受体都通过相似的细胞内区室进行转运。综上所述,这些数据表明,当利用二硫键还原进行细胞内药物释放时,必须针对每个受体转运途径独立分析二硫键还原的效率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/15ea47818aae/cdr-4-223.fig.4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/efd185ab5b65/cdr-4-223.fig.1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/d8d92c4cfab5/cdr-4-223.fig.2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/ffbc7aabfde9/cdr-4-223.fig.3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/15ea47818aae/cdr-4-223.fig.4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/efd185ab5b65/cdr-4-223.fig.1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/d8d92c4cfab5/cdr-4-223.fig.2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/ffbc7aabfde9/cdr-4-223.fig.3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e682/9019189/15ea47818aae/cdr-4-223.fig.4.jpg

相似文献

1
Evaluation of the reducing potential of PSMA-containing endosomes by FRET imaging.通过荧光共振能量转移成像评估含前列腺特异性膜抗原(PSMA)的内体的还原电位。
Cancer Drug Resist. 2021 Mar 19;4(1):223-232. doi: 10.20517/cdr.2020.84. eCollection 2021.
2
Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging.利用荧光共振能量转移成像评估受体介导的内吞作用过程中二硫键的还原。
Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13872-7. doi: 10.1073/pnas.0601455103. Epub 2006 Sep 1.
3
Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates.内体和溶酶体的氧化电位限制了基于二硫键的抗体-药物偶联物的细胞内裂解。
Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):17987-92. doi: 10.1073/pnas.0509035102. Epub 2005 Dec 1.
4
Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.使用 DUPA-紫杉醇缀合物对前列腺癌进行前列腺特异性膜抗原靶向治疗。
Mol Pharm. 2018 May 7;15(5):1842-1852. doi: 10.1021/acs.molpharmaceut.8b00026. Epub 2018 Apr 5.
5
Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates.含叶酸受体的内体的pH值表征以及内化的酸不稳定叶酸-药物偶联物的水解速率
J Pharmacol Exp Ther. 2007 May;321(2):462-8. doi: 10.1124/jpet.106.117648. Epub 2007 Feb 8.
6
Characterization of in vivo disulfide-reduction mediated drug release in mouse kidneys.体内二硫键还原介导的药物在小鼠肾脏中的释放特性。
Mol Pharm. 2012 Feb 6;9(2):310-7. doi: 10.1021/mp200483t. Epub 2012 Jan 9.
7
Development of a Cysteine-Conjugatable Disulfide FRET Probe: Influence of Charge on Linker Cleavage and Payload Trafficking for an Anti-HER2 Antibody Conjugate.半胱氨酸键合的二硫键 FRET 探针的研制:荷质比对连接子断裂和抗 HER2 抗体缀合物有效载荷转运的影响。
Bioconjug Chem. 2019 Dec 18;30(12):3046-3056. doi: 10.1021/acs.bioconjchem.9b00678. Epub 2019 Dec 3.
8
Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells.前列腺癌细胞对HPMA共聚物-抗PSMA抗体缀合物的生物识别与亚细胞转运
Mol Pharm. 2009 May-Jun;6(3):959-70. doi: 10.1021/mp8002682.
9
Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand.使用前列腺特异性膜抗原(PSMA)抑制剂作为归巢配体的前列腺癌靶向成像与治疗。
Mol Pharm. 2009 May-Jun;6(3):780-9. doi: 10.1021/mp900069d.
10
Tagging Transferrin Receptor with a Disulfide FRET Probe To Gauge the Redox State in Endosomal Compartments.用二硫键荧光共振能量转移探针标记转铁蛋白受体,以评估内体隔室中的氧化还原状态。
Anal Chem. 2020 Sep 15;92(18):12460-12466. doi: 10.1021/acs.analchem.0c02264. Epub 2020 Aug 3.

引用本文的文献

1
Selective targeting of chemically modified miR-34a to prostate cancer using a small molecule ligand and an endosomal escape agent.使用小分子配体和内体逃逸剂将化学修饰的miR-34a选择性靶向前列腺癌。
Mol Ther Nucleic Acids. 2024 Apr 23;35(2):102193. doi: 10.1016/j.omtn.2024.102193. eCollection 2024 Jun 11.
2
Recent advances in tumor-targeting chemotherapy drugs.肿瘤靶向化疗药物的最新进展。
Cancer Drug Resist. 2021;4(4):885-887. doi: 10.20517/cdr.2021.86. Epub 2021 Sep 8.

本文引用的文献

1
Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC).肿瘤靶向药物偶联物作为小细胞肺癌(SCLC)中一种新兴的新型治疗方法。
Cancers (Basel). 2019 Sep 3;11(9):1297. doi: 10.3390/cancers11091297.
2
Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate.自毁基团连接的前列腺特异性膜抗原特异性抗肿瘤活性。
Bioconjug Chem. 2019 Jun 19;30(6):1805-1813. doi: 10.1021/acs.bioconjchem.9b00335. Epub 2019 May 22.
3
Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy.
靶向前列腺癌:基于前列腺特异性膜抗原的诊断和治疗。
Med Res Rev. 2019 Jan;39(1):40-69. doi: 10.1002/med.21508. Epub 2018 May 17.
4
Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA).通过前列腺特异性膜抗原(PSMA)将叶酸偶联脂质体与共包封药物靶向递送至前列腺癌细胞。
Nanomedicine. 2018 Jun;14(4):1407-1416. doi: 10.1016/j.nano.2018.04.011. Epub 2018 Apr 19.
5
Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.使用 DUPA-紫杉醇缀合物对前列腺癌进行前列腺特异性膜抗原靶向治疗。
Mol Pharm. 2018 May 7;15(5):1842-1852. doi: 10.1021/acs.molpharmaceut.8b00026. Epub 2018 Apr 5.
6
Intraindividual Comparison of F-PSMA-1007 and F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study.个体内比较 F-PSMA-1007 和 F-DCFPyL PET/CT 在新诊断前列腺癌患者中的前瞻性评估:一项初步研究。
J Nucl Med. 2018 Jul;59(7):1076-1080. doi: 10.2967/jnumed.117.204669. Epub 2017 Dec 21.
7
Ligand-Targeted Drug Delivery.配体靶向药物递送。
Chem Rev. 2017 Oct 11;117(19):12133-12164. doi: 10.1021/acs.chemrev.7b00013. Epub 2017 Sep 12.
8
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.使用¹⁷⁷Lu标记的PSMA-617对转移性去势抵抗性前列腺癌进行PSMA靶向放射性核素治疗。
J Nucl Med. 2016 Aug;57(8):1170-6. doi: 10.2967/jnumed.115.171397. Epub 2016 Mar 16.
9
Endocytic pathways and endosomal trafficking: a primer.内吞途径与内体运输:入门指南
Wien Med Wochenschr. 2016 May;166(7-8):196-204. doi: 10.1007/s10354-016-0432-7. Epub 2016 Feb 9.
10
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.PSMA 靶向载多西紫杉醇纳米颗粒 BIND-014 治疗晚期实体瘤患者的 I 期研究。
Clin Cancer Res. 2016 Jul 1;22(13):3157-63. doi: 10.1158/1078-0432.CCR-15-2548. Epub 2016 Feb 4.